PRQR — ProQR Therapeutics NV Cashflow Statement
0.000.00%
Last trade - 00:00- $199.27m
- $109.67m
- €16.35m
Annual cashflow statement for ProQR Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -61.7 | -64.9 | -27.7 | -27.8 | -42.2 |
| Depreciation | |||||
| Non-Cash Items | 10.7 | 3.04 | -4.07 | -0.805 | -9.71 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 22.6 | -9.18 | 50.8 | -10.6 | -3.6 |
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -26 | -68.5 | 21.5 | -36.4 | -52.8 |
| Capital Expenditures | -0.484 | -0.708 | -1.37 | -1.42 | -1.02 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.059 | 0.006 | 5.65 | -2.65 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.425 | -0.702 | 4.28 | -4.07 | -1.02 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 137 | -30.9 | -2.27 | 70.3 | -1.84 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 112 | -92.7 | 24.1 | 30.5 | -57 |